ISRCTN57761809CompletedNot Applicable
Effect of anti-tumour necrosis factor alpha (TNFa) therapy on endothelial function and other surrogate markers of cardiovascular disease in patients with rheumatoid arthritis
niversity of Dundee (UK)0 sites90 target enrollmentStarted: May 9, 2008Last updated:
Conditions
Trial Snapshot
- Phase
- Not Applicable
- Status
- Completed
- Sponsor
- Enrollment
- 90
Study Overview
Brief Summary
No summary available.
Study Design
- Study Type
- Observational
Eligibility Criteria
- Sex
- All
Inclusion Criteria
- •1. Both males and females, 18 years old or over
- •2. Fulfil the 1987 American College of Rheumatology (ACR) classification criteria for rheumatoid arthritis
- •3. No exposure to anti-TNFa drugs in the last 3 months
- •4. Fulfil the National Institute for Clinical Excellence guidelines on the use of anti-TNFa drugs in rheumatoid arthritis* and be:
- •4.1. About to start etanercept or adalimumab (treatment group)
- •4.2. About to start methotrexate (control group)
- •* The patients in the control group must have had adequate therapeutic trial of at least one previous Disease Modifying Anti-Rheumatic Drug (DMARD) rather than two
Exclusion Criteria
- •1. Previous cardiovascular or cerebrovascular event in the last 3 years
- •2. Undergoing treatment for a cardiovascular risk factor except:
- •2.1. Patients with hypertension on stable medication for the last 3 months
- •2.2. Patients with hypercholesterolaemia on stable medication for the last 3 months
Investigators
Similar Trials
Recruiting
Not Applicable
Impact of anti-tumor necrosis factor antibodies treatment on the semen quality of inflammatory bowel diseases patientsfertilityreproduction10013356NL-OMON33788Erasmus MC, Universitair Medisch Centrum Rotterdam20
Active, not recruiting
Not Applicable
Impact of anti-tumor necrosis factors antibodies treatment on fertility of inflammatory bowel diseases male patientsFertility influenced by antiTNF treatmentMedDRA version: 9.1Level: LLTClassification code 10016469Term: Fertility investigationsEUCTR2008-005619-16-NLErasmus Medical Center
Completed
Not Applicable
The safety of anti-tumor necrosis factor-alpha (TNF-a) agents in pregnancy. An observational prospective multicenter study.P04.1Fetus and newborn affected by other maternal medicationDRKS00005036Pharmakoivigilanz- und Beratungszentrum für Embryonaltoxikologie, Charité Berlin625
Completed
Not Applicable
Anti-tumour necrosis factor (anti-TNF) therapy over two years increases body fat mass in early rheumatoid arthritisMusculoskeletal DiseasesOther rheumatoid arthritisRheumatoid arthritisISRCTN39045408Karolinska University Hospital (Sweden)40
Active, not recruiting
Phase 1
Effectiveness of anti TNFalpha agents in Behcet¿s diseaseBEH¿ET¿S DISEASE REFRACTORY TO STANDARD OF CARE THERAPIESMedDRA version: 20.0Level: LLTClassification code 10004215Term: Behcets diseaseSystem Organ Class: 100000004866EUCTR2017-000845-39-ITAZIENDA OSPEDALIERO-UNIVERSITARIA PISANA46